Emcure Pharmaceuticals has entered into a Share Subscription and Shareholders’ Agreement and Power Transfer Agreement(s) dated June 02, 2025 to purchase the electricity generated from Torrent Urja 37 (TUPL), in accordance with the provisions of the aforesaid Agreement(s) to meet its energy requirements at identified facilities in the state of Gujarat. Cost of acquisition is Rs 3.72 crore.
The completion of the acquisition is subject to the receipt of all consents, permissions required to be obtained by TUPL from regulatory authority for open access for captive consumption of electricity.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1279.70 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2245.65 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: